EGFR/HDAC-IN-1

EGFR/HDAC-IN-1 (Compound 22c2) is a potent dual inhibitor of epidermal growth factor receptor (EGFR) and histone deacetylase (HDAC) with IC50 values of 4.81 nM, 119.4 nM and 354.8 nM for EGFR, HDAC1 and HDAC3, respectively. EGFR/HDAC-IN-1 blocks the EGFR signaling pathway and affects the histone acetylation status, thereby inhibiting tumor cell proliferation. EGFR/HDAC-IN-1 is promising for research of non-small cell lung cancer (NSCLC) [1].

Product Specifications

UNSPSC

12352005

Target

EGFR; HDAC

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Smiles

O=C(NO)CCCCCOC1=C2C(OCCO2)=C3C(NC4=CC(Cl)=CC=C4)=NC=NC3=C1

Molecular Formula

C22H23ClN4O5

Molecular Weight

458.89

References & Citations

[1]Yao K, et al. Synthesis and biological evaluation of novel 4-Arylaminoquinolines derivatives as EGFR/HDAC inhibitors. Bioorg Med Chem Lett. 2025 Jul 1;122:130214.